-
1 Comment
Seikagaku Corporation is currently in a long term uptrend where the price is trading 3.6% above its 200 day moving average.
From a valuation standpoint, the stock is 96.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Seikagaku Corporation's total revenue sank by 5.3% to $7B since the same quarter in the previous year.
Its net income has dropped by 8.3% to $903M since the same quarter in the previous year.
Based on the above factors, Seikagaku Corporation gets an overall score of 2/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| ISIN | JP3414000004 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Target Price | 1950 |
|---|---|
| Market Cap | 38B |
| PE Ratio | 19.05 |
| Dividend Yield | 4.3% |
| Beta | 0.28 |
Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally.The company operates in two segments, Pharmaceuticals and LAL Business. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, VISCO-3, JOYCLU Gel-One, Hylink, and SUPARTZ FX; ophthalmic surgical aids under the OPEGAN and SHELLGAN brands; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and HERNICORE for the treatment of lumbar disc herniation. The company also offers bulk products comprising sodium hyaluronate and sodium chondroitin sulfate for use in pharmaceuticals and cosmetics. In addition, it develops endotoxin-detecting reagents for use in quality control of injectable pharmaceuticals and medical devices manufacturing processes and water quality control of dialysate under the brands, such as Pyrochrome, ENDOSPECY, TOXICOLOR, etc. Additionally, its products under development include SI-6603 for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; SI-613 for knee osteoarthritis; SI-722 to treat interstitial cystitis and bladder pain syndrome; SI-613-ETP to treat enthesopathy; and SI-449, a cross-linked chondroitin sulfate adhesion barrier. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4548.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
